The ACR is also steadfastly committed to ensuring that the voice of rheumatology is well-represented in the Medicare Drug Price Negotiation Program, that the drugs selected for negotiation adequately represent what rheumatologists are experiencing in the field and that these drugs are adequately priced.
For further information on the program, email the ACR advocacy team at [email protected] or contact the CMS at [email protected]. The ACR advocacy team will monitor the implementation of the program and other provisions of the IRA and serve as an educational resource for members on its impact on rheumatology.
